Video
Dr. Yardley Discusses CDK4/6 Inhibitors for Breast Cancer
Author(s):
Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses CDK4/6 inhibitors for patients with breast cancer.
Denise A. Yardley, MD, senior investigator of breast cancer research, Sarah Cannon Research Institute, discusses CDK4/6 inhibitors for patients with breast cancer.
PALOMA-1 data investigated the clinical science of CDK4/6 inhibitors and demonstrated that they could affect outcomes and double the disease-free survival for patients with hormone receptor-positive breast cancer. The PALOMA-1 trial led to the accelerated approval of palbociclib (Ibrance) in the first-line setting for that patient population.
The confirmatory PALOMA-2 trial further demonstrated that the signal seen with CDK4/6 inhibitors was real and reproducible. PALOMA-3 investigated patients who had failed prior endocrine therapy and then received fulvestrant (Faslodex) with a CDK4/6 inhibitor.
